Recommendations for the clinical use of cyclooxygenase-2-specific inhibitors

American Journal of Medicine

Volumn 110, Issue 3 SUPPL. 1, 2001, Pages 3-5

  Lipsky, Peter E ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT;

ALGORITHM; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 0035911021     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00680-x     Document Type: Review

References (11)

1. Cyclooxygenase in biology and disease
2. The discovery and function of COX-2
3. Biologic effects of nonsteroidal anti-inflammatory drugs
4. The mechanisms of action of NSAIDs in analgesia
5. The classification of cyclooxygenase inhibitors
6. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor
7. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip OA in a 6-week controlled clinical trial
8. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
9. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized, controlled trial
10. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice
11. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis